CRH · NYSE
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Total Revenue | $37.45B | $35.57B | $34.95B | $32.72B | $29.21B |
| Cost of Revenue | $23.92B | $22.87B | $22.99B | $21.91B | $19.38B |
| Gross Profit | $13.53B | $12.70B | $11.96B | $10.81B | $9.83B |
| Selling, General & Administrative | $8.28B | $7.85B | $7.49B | $7.06B | $6.54B |
| Operating Income | $5.44B | $4.92B | $4.19B | $3.81B | $3.33B |
| Interest Expense | — | — | $376.00M | $344.00M | $315.00M |
| Other Income / (Expense) | $29.00M | $258.00M | -$2.00M | -$69.00M | $90.00M |
| Income Before Taxes | $4.80B | $4.71B | $4.01B | $3.46B | $3.10B |
| Provision for Income Taxes | $1.04B | $1.08B | $925.00M | $762.00M | $650.00M |
| Net Income | $3.75B | $3.49B | $3.18B | $3.86B | $2.63B |
| Basic EPS | $5.54 | $5.06 | $4.36 | $5.15 | $3.35 |
| Diluted EPS | $5.51 | $5.02 | $4.33 | $5.11 | $3.32 |
| Basic Shares Outstanding | 673.20M | 683.30M | 723.90M | 758.30M | 780.20M |
| Diluted Shares Outstanding | 677.00M | 689.50M | 729.20M | 764.10M | 786.80M |
| Period | Consensus EPS | Low | High | Estimates | Revisions |
|---|---|---|---|---|---|
| Dec 2026 | $5.80 | $5.74 | $5.85 | 2 | ↑0 ↓1 |
| Dec 2027 | $6.68 | $6.48 | $6.84 | 5 | ↑1 ↓1 |
| Dec 2028 | $7.35 | $7.22 | $7.49 | 4 | ↑1 ↓1 |
| Dec 2029 | $8.46 | $8.46 | $8.46 | 1 | ↑0 ↓0 |